Hemophilia A is a common X chromosome-linked genetic
bleeding disorder caused by abnormalities in the
coagulation factor VIII gene (F8).
Hemophilia A patients suffer from a
bleeding diathesis, such as life-threatening
bleeding in the brain and harmful
bleeding in joints and muscles. Because it could potentially be cured by gene therapy, subhuman animal models have been sought. Current mouse
hemophilia A models generated by gene targeting of the F8 have difficulties to extrapolate human disease due to differences in the coagulation and immune systems between mice and humans. Here, we generated a porcine model of
hemophilia A by nuclear transfer cloning from F8-targeted fibroblasts. The
hemophilia A pigs showed a severe
bleeding tendency upon birth, similar to human severe hemophiliacs, but in contrast to
hemophilia A mice which rarely bleed under standard breed conditions. Infusion of human
factor VIII was effective in stopping
bleeding and reducing the
bleeding frequency of a
hemophilia A piglet but was blocked by the inhibitor against human
factor VIII. These data suggest that the
hemophilia A pig is a severe
hemophilia A animal model for studying not only
hemophilia A gene therapy but also the next generation recombinant
coagulation factors, such as recombinant
factor VIII variants with a slower clearance rate.